Hypoactive sexual desire disorder (HSDD)

Dr. Alyssa Dweck discusses this condition that many women are uncomfortable talking to their healthcare providers about. Hypoactive sexual desire disorder or HSDD is biological and not a result of issues or unhappiness. It can be handled with proper care and treatment. Learn more at Vyleesi. PRODUCT IS ONLY APPROVED FOR USE IN THE U.S.

Read More

Improve access to care for people living with epilepsy

Mike Davis, Head of the U.S. Neurology Patient Value Unit at UCB, a global pharmaceutical company, discusses the collaboration with the University of Washington’s School of Pharmacy to improve access to care for people living with epilepsy. This interdisciplinary project will explore ways in which community pharmacists can better support people living with this neurological disorder.

Read More

New Investigational Drug for HSV

New CEO of Squarex, Jack V. Talley discusses the positive results of the phase 2 study on their new investigational drug candidate SQX770, a topical immunomodulator treatment to extend the time between herpes labialis (recurrent cold sores) outbreaks caused by Herpes Simplex Virus 1 or Herpes Simplex Virus 2.  Squarex is a clinical-stage pharmaceutical company.

Read More

Kleo Pharmaceuticals – Immuno-Oncology Drugs

Kleo Pharmaceuticals is a unique immuno-oncology company poised to solve some of the problems dominating the headlines for the biopharmaceutical industry. CEO Dr. Doug Manion discusses the development of next-generation bispecific compounds designed to emulate or enhance the activity of biologics, which directly engage patients’ immune systems to target and destroy cancer cells. Human studies are anticipated in 2020.

Read More